Investors & Media

Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™

–       Interim analysis of B-Clear clinical study of bepirovirsen demonstrated end-of-treatment virologic response (VR) in patients with chronic hepatitis B –       Phase 3 clinical study evaluating b epirovirsen as a monotherapy is anticipated to start in the first half of 2023 –       GSK to

Read more
You are now leaving to visit